BioNanomatrix will apply its nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.
"This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix.
"We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing," he said.
BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format.
The company's patented analytic platform based on this technology has the potential to provide ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.
Further details of the agreement were not disclosed.